Epidemiology of Parkinson’s Disease: An Overview

Parkinson's Disease

Volumn , Issue , 2004, Pages 39-50

  Korell, Monica ^a   Tanner, Caroline M ^a  

^a PARKINSON S INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85160144125     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203508596-15     Document Type: Chapter

References (123)

1. Mutch, W. J. et al., Parkinson’s disease in a Scottish city, Br. Med. J. (Clin. Res. Ed.), 292, pp. 534-536, 1986.
2. Marttila, R. J. and U. K. Rinne, Epidemiology of Parkinson’s disease in Finland, Acta Neurol. Scand., 53, pp. 81-102, 1976.
3. Anderson, D. W. et al., Case ascertainment uncertainties in prevalence surveys of Parkinson’s disease, Mov. Disord., 13, pp. 626-32, 1998.
4. Schoenberg, B. S., D.W. Anderson, and A. F. Haerer, Prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi, Neurology, 35, pp. 841-845, 1985.
5. Morgante, L. et al., Prevalence of Parkinson’s disease and other types of parkinsonism: A door-to-door survey in three Sicilian municipalities, The Sicilian Neuro-Epidemiologic Study (SNES) Group, Neurology, 42, pp. 1901-1907, 1992.
6. de Rijk, M. C. et al., Prevalence of Parkinson’s disease in the elderly: The Rotterdam Study, Neurology, 45, pp. 2143-2146, 1995.
7. Twelves, D., K. S. Perkins, and C. Counsell, Systematic review of incidence studies of Parkinson’s disease, Mov. Disord., 18, pp. 19-31, 2003.
8. Rosati, G. et al., The risk of Parkinson disease in Mediterranean people, Neurology, 30, pp. 250-255, 1980.
9. Rajput, A. H. et al., Epidemiology of parkinsonism: Incidence, classification, and mortality, Ann. Neurol., 16, pp. 278-282, 1984.
10. Zhang, Z. X. and G. C. Roman, Worldwide occurrence of Parkinson’s disease: An updated review, Neuroepidemiology, 12, pp. 195-208, 1993.
11. Uitti, R. J. et al., Levodopa therapy and survival in idiopathic Parkinson’s disease: Olmsted County project, Neurology, 43, pp. 1918-1926, 1993.
12. Chen, R. C. et al., Prevalence, incidence, and mortality of PD: A door-to-door survey in Ilan county, Taiwan, Neurology, 57, pp. 1679-86, 2001.
13. Morens, D. M. et al., Epidemiologic observations on Parkinson’s disease: Incidence and mortality in a prospective study of middle-aged men, Neurology, 46, pp. 1044-1050, 1996.
14. Poewe, W., The Sydney multicentre study of Parkinson’s disease, J. Neurol. Neurosurg. Psychiatry, 67, pp. 280-281, 1999.
15. Mayeux, R. et al., The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan, 1988-1993, Am. J. Epidemiol., 142, pp. 820-827, 1995.
16. Kuopio, A. M. et al., Changing epidemiology of Parkinson’s disease in southwestern Finland, Neurology, 52, pp. 302-308, 1999.
17. Fall, P. A. et al., Age-standardized incidence and prevalence of Parkinson’s disease in a Swedish community, J. Clin. Epidemiol., 49, pp. 637-641, 1996.
18. Bower, J. H. et al., Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990, Neurology, 52, pp. 1214-1220, 1999.
19. Baldereschi, M. et al., Parkinson’s disease and parkinsonism in a longitudinal study: Two-fold higher incidence in men. ILSA Working Group, Italian Longitudinal Study on Aging, Neurology, 55, pp. 1358-1363, 2000.
20. Leentjens, A. F. et al., The incidence of Parkinson’s disease in the Netherlands: Results from a longitudinal general practice-based registration, Neuroepidemiology, 22, pp. 311-312, 2003.
21. Tanner, C. M. and J. W. Langston, Do environmental toxins cause Parkinson’s disease? A critical review, Neurology, 40, pp. suppl. 17-30; discussion 30-1, 1990.
22. Van Den Eeden, S. K., et al., Incidence of Parkinson’s disease: Variation by age, gender, and race/ethnicity, Am. J. Epidemiol., 157, pp. 1015-1022, 2003.
23. Taba, P. and T. Asser, Incidence of Parkinson’s disease in estonia, Neuroepidemiology, 22, pp. 41-45, 2003.
24. Ashok, P. P. et al., Epidemiology of Parkinson’s disease in Benghazi, North-East Libya, Clin. Neurol. Neurosurg., 88, pp. 109-113, 1986.
25. Taba, P. and T. Asser, Prevalence of Parkinson’s disease in Estonia, Acta Neurol. Scand., 106, pp. 276-281, 2002.
26. Kusumi, M. et al., Epidemiology of Parkinson’s disease in Yonago City, Japan: Comparison with a study carried out 12 years ago, Neuroepidemiology, 15, pp. 201-207, 1996.
27. Kimura, H. et al., Female preponderance of Parkinson’s disease in Japan, Neuroepidemiology, 21, pp. 292, 2002.
28. Tanner, C M. and D. A. Aston, Epidemiology of Parkinson’s disease and akinetic syndromes, Curr. Opin. Neurol., 13, pp. 427-430, 2000.
29. Schoenberg, B. S. et al., Comparison of the prevalence of Parkinson’s disease in black populations in the rural United States and in rural Nigeria: Door-to-door community studies, Neurology, 38, pp. 645-646, 1988.
30. Rocca, W. A. et al., Time trends in the incidence of parkinsonism in Olmsted County, Minnesota, Neurology, 57, pp. 462-467, 2001.
31. Tanner, C. M. et al., Parkinson’s disease incidence in Olmsted County, MN: 1935-1988, Neurology, 42, pp. 194-194, 1992.
32. Li, S. C. et al., A prevalence survey of Parkinson’s disease and other movement disorders in the People’s Republic of China, Arch. Neurol., 42, pp. 655-657, 1985.
33. Wang, Y. S. et al., Parkinson’s disease in China. Coordinational Group of Neuroepidemiology, PLA, Chin. Med. J. (Engl.), 104, pp. 960-964, 1991.
34. Wang, S. J. et al., A door-to-door survey of Parkinson’s disease in a Chinese population in Kinmen, Arch. Neurol., 53, pp. 66-71, 1996.
35. Zhang, Z. X. et al., Prevalence of Parkinson’s disease and related disorders in the elderly population of greater Beijing, China, Mov. Disord., 18, pp. 764-772, 2003.
36. Polymeropoulos, M. et al., Mutation in the α-synuclein gene identified in families with Parkinson’s disease, Science, pp. 2045-2047, 1997.
37. Golbe, L. I. et al., Clinical genetic analysis of Parkinson’s disease in the Contursi kindred, Ann. Neurol., 40, pp. 767-775, 1996.
38. Kruger, R., et al., Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease, Nat. Genet., 18, pp. 106-108, 1998.
39. Hattori, N. et al., Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in the Parkin gene in affected individuals, Ann. Neurol., 44, pp. 935-941, 1998.
40. Kitada, T. et al., Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, Nature, 392, pp. 605-608, 1998.
41. Bonifati, V. et al., Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism, Science, 299, pp. 256-259, 2003.
42. Farrer, M., et al. A chromosome 4p haplotype segregating with Parkinson’s disease and postural tremor, Hum. Mol. Genet., 8, pp. 81-85, 1999.
43. Funayama, M. et al., A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2-q13.1, Ann. Neurol., 51, pp. 296-301, 2002.
44. Gasser, T. et al., A susceptibility locus for Parkinson’s disease maps to chromosome 2p13, Nat. Genet., 18, pp. 262-265, 1998.
45. Hicks, A. A. et al., A susceptibility gene for late-onset idiopathic Parkinson’s disease, Ann. Neurol., 52, pp. 549-555, 2002.
46. Leroy, E. et al., The ubiquitin pathway in Parkinson’s disease, Nature, 395, pp. 451-452, 1998.
47. Valente, E. M. et al., Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36, Am. J. Hum. Genet., 68, pp. 895-900, 2001.
48. van Duijn, C. M. et al., Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36, Am. J. Hum. Genet., 69, pp. 629-634, 2001.
49. Wooten, G. F. et al., Maternal inheritance in Parkinson’s disease, Ann. Neurol., 41, pp. 265-268, 1997.
50. Swerdlow, R. H. et al., Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson’s disease family, Ann. Neurol., 44, pp. 873-881, 1998.
51. Farrer, M. et al., Low frequency of alpha-synuclein mutations in familial Parkinson’s disease, Ann. Neurol., 43, pp. 394-397, 1998.
52. Papadimitriou, A. et al., Mutated alpha-synuclein gene in two Greek kindreds with familial PD: Incomplete penetrance?, Neurology, 52, pp. 651-654, 1999.
53. Abbas, N. et al., A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe, Hum. Mol. Genet., 8, pp. 567-574, 1999.
54. Wang, M. et al., Polymorphism in the parkin gene in sporadic Parkinson’s disease, Ann. Neurol., 45, pp. 655-658, 1999.
55. Autere, J. M. et al., Familial aggregation of Parkinson’s disease in a Finnish population, J. Neurol. Neurosurg. Psychiatry, 69, pp. 107-109, 2000.
56. Payami, H. et al., Increased risk of Parkinson’s disease in parents and siblings of patients, Annals of Neurology, 36, pp. 659-661, 1994.
57. Elbaz, A. et al., Validity of family history data on PD: Evidence for a family information bias, Neurology, 61, pp. 11-17, 2003.
58. Tanner, C. M. et al., Parkinson disease in twins: An etiologic study, Jama, 281, pp. 341-346, 1999.
59. Piccini, P. et al., The role of inheritance in sporadic Parkinson’s disease: Evidence from a longitudinal study of dopaminergic function in twins, Ann. Neurol., 45, pp. 577-582, 1999.
60. Vieregge, P. et al., Parkinson’s disease in twins: A followup study, Neurology, 53, pp. 566-572, 1999.
61. Langston, J. W. et al., Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis, Science, 219, pp. 979-980, 1983.
62. Burns, R. S. et al., A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Proceedings of the National Academy of Sciences, 80, pp. 4546-4550, 1983.
63. Langston, J. W. et al., Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey, Brain Research, 292, pp. 390-394, 1984.
64. Seidler, A. et al., Possible environmental, occupational, and other etiologic factors for Parkinson’s disease: A case-control study in Germany, Neurology, 46, pp. 1275-1284, 1996.
65. Semchuk, K. M., Love, E. J. and Lee, R. G., Parkinson’s disease and exposure to agricultural work and pesticide chemicals, Neurology, 42, pp. 1328-1335, 1992.
66. Gorell, J. M. et al., The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living, Neurology, 50, pp. 1346-1350, 1998.
67. Koller, W. et al., Environmental risk factors in Parkinson’s disease, Neurology, 40, pp. 1218-1221, 1990.
68. De Michele, G. et al., Environmental and genetic risk factors in Parkinson’s disease: A case-control study in southern Italy, Mov. Disord., 11, pp. 17-23, 1996.
69. Wong, G. F. et al., Environmental risk factors in siblings with Parkinson’s disease, Arch. Neurol., 48, pp. 287-289, 1991.
70. Liou, H. H. et al., Environmental risk factors and Parkinson’s disease: A case-control study in Taiwan, Neurology, 48, pp. 1583-1588, 1997.
71. Fleming, L. et al., Parkinson’s disease and brain levels of organochlorine pesticides, Ann. Neurol., 36, pp. 100-103, 1994.
72. Tanner, C. M. et al., Environmental factors and Parkinson’s disease: A case-control study in China, Neurology, 39, pp. 660-664, 1989.
73. Ho, S. C., Woo, J., and Lee, C. M., Epidemiologic study of Parkinson’s disease in Hong Kong, Neurology, 39, pp. 1314-1318, 1989.
74. Tanner, C. M. and Goldman, S. M., Epidemiology of Parkinson’s disease, Neurol. Clin., 14, pp. 317-335, 1996.
75. Gorell, J. M. et al., Occupational metal exposures and the risk of Parkinson’s disease, Neuroepidemiology, 18, pp. 303-308, 1999.
76. Schulte, P. A. et al., Neurodegenerative diseases: Occupational occurrence and potential risk factors, 1982 through 1991, Am. J. Public Health, 86, pp. 1281-1288, 1996.
77. Herishanu, Y. O. et al., A case-control study of Parkinson’s disease in urban population of southern Israel, Can. J. Neurol. Sci., 28, pp. 144-147, 2001.
78. Fall, P. A. et al., Nutritional and occupational factors influencing the risk of Parkinson’s disease: A case-control study in southeastern Sweden, Mov. Disord., 14, pp. 28-37, 1999.
79. Semchuk, K M., Love, E. J., and Lee, R. G., Parkinson’s disease: A test of the multifactorial etiologic hypothesis, Neurology, 43, pp. 1173-1180, 1993.
80. Stern, M. et al., The epidemiology of Parkinson’s disease. A case-control study of young-onset and old-onset patients, Arch. Neurol., 48, pp. 903-907, 1991.
81. Tsai, C. H. et al., Environmental risk factors of young onset Parkinson’s disease: A case-control study, Clin. Neurol. Neurosurg, 104, pp. 328-333, 2002.
82. Tanner, C. M. et al., Environmental factors in the etiology of Parkinson’s disease, Can. J. Neurol. Sci., 14, pp. 419-423, 1987.
83. Hofman, A., Collette, H. J., and Bartelds, A. I., Incidence and risk factors of Parkinson’s disease in The Netherlands, Neuroepidemiology, 8, pp. 296-269, 1989.
84. Morano, A. et al., Risk-factors for Parkinson’s disease: Case-control study in the province of Caceres, Spain, Acta Neurol. Scand., 89, pp. 164-170, 1994.
85. Bower, J. H. et al., Head trauma preceding PD: A casecontrol study, Neurology, 60, pp. 1610-1615, 2003.
86. Poskanzer, D. C., Schwab, R. S., and Fraser, D. W., Further observations on the cohort phenomenon in Parkinson’s syndrome, in Progress in Neurogenetics, A. Barbeau and J. R. Brunette, Eds., 1969, Excerpta Medica Foundation: Amsterdam, pp. 497-505.
87. Kobbata, S. and B.L. Beaman, L-dopa-responsive movement disorder caused by Norcardia asteroides localized in the brains of mice, Infect Immun, 59, pp. 181-191, 1991.
88. Hubble, J. P. et al., Nocardia species as an etiologic agent in Parkinson’s disease: Serological testing in a case-control study, J. Clin. Microbiol., 33, pp. 2768-2769, 1995.
89. Tanner, C. et al., Occupation and risk of Parkinson’s disease (PD): A preliminary investigation of Standard Occupational Codes (SOC) in twins discordant for disease, Neurology, 60, p. A415, 2003.
90. Tsui, J. K. et al., Occupational risk factors in Parkinson’s disease, Can J Public Health, 90, pp. 334-337, 1999.
91. Zayed, J. et al., Environmental factors in the etiology of Parkinson’s disease, Can. J. Neurol. Sci., 17, pp. 286-291, 1990.
92. Tanner, C. M. et al., Smoking and Parkinson’s disease in twins, Neurology, 58, pp. 581-588, 2002.
93. Ross, G. W. and Petrovitch, H., Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson’s disease, Drugs Aging, 18, pp. 797-806, 2001.
94. Smargiassi, A. et al., A case-control study of occupational and environmental risk factors for Parkinson’s disease in the Emilia-Romagna region of Italy, Neurotoxicology, 19, pp. 709-712, 1998.
95. Taylor, C. A. et al., Environmental, medical, and family history risk factors for Parkinson’s disease: A New England-based case control study, Am. J. Med. Genet., 88, pp. 742-749, 1999.
96. Checkoway, H. et al., Parkinson’s disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake, Am. J. Epidemiol., 155, pp. 732-738, 2002.
97. Hernan, M. A. et al., A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease, Ann. Neurol., 52, pp. 276-284, 2002.
98. Tanner, C. et al., Cigarette smoking, alcohol drinking and Parkinson’s disease: Cross-cultural risk assessment., Mov. Disord., 5, p. 11, 1990.
99. Grandinetti, A. et al., Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson’s disease, Am. J. Epidemiol., 139, pp. 1129-1138, 1994.
100. Gorell, J. M. et al., Smoking and Parkinson’s disease: A dose-response relationship, Neurology, 52, pp. 115-119, 1999.
101. Mayeux, R. et al., Smoking and Parkinson’s disease, Mov Disord, 9, pp. 207-212, 1994.
102. Rajput, A. H. et al., A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson’s disease, Neurology, 37, pp. 226-232, 1987.
103. Fowler, J. et al., Inhibition of monoamine oxidase B in the brains of smokers., Nature, 379, pp. 733-736, 1996.
104. Mendez-Alvarez, E. et al., Inhibition of brain monoamine oxidase by adducts of 1,2,3,4-tetrahydroisoquinoline with components of cigarette smoke, Life Sciences, 60, pp. 1719-1727, 1997.
105. Salach, J. I. et al., Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP, Biochem. Biophys. Res. Commun., 125, pp. 831-835, 1984.
106. Ferger, B. et al., Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo, Naunyn Schmiedebergs Arch. Pharmacol., 358, pp. 351-359, 1998.
107. Ascherio, A. et al., Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women, Ann. Neurol., 50, pp. 56-63, 2001.
108. Ross, G. W. et al., Association of coffee and caffeine intake with the risk of Parkinson disease, Jama, 283, pp. 2674-2679, 2000.
109. Paganini-Hill, A., Risk factors for Parkinson’s disease: The leisure world cohort study, Neuroepidemiology, 20, pp. 118-124, 2001.
110. Ascherio, A. et al., Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease, Neurology, 60, pp. 790-795, 2003.
111. Popoli, P., Caporali, M. G., and Scotti de Carolis, A., Akinesia due to catecholamine depletion in mice is prevented by caffeine. Further evidence for an involvement of adenosinergic system in the control of motility, J. Pharm. Pharmacol., 43, pp. 280-281, 1991.
112. Nehlig, A., Daval, J. L. and Debry, G., Caffeine and the central nervous system: Mechanisms of action, biochemical, metabolic and psychostimulant effects, Brain Res. Brain Res. Rev., 17, pp. 139-170, 1992.
113. Kanda, T. et al., Adenosine A2A receptors modify motor function in MPTP-treated common marmosets, Neuroreport, 9, pp. 2857-2860, 1998.
114. Richardson, P., Kase, H., and Jenner, P., Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson’s disease., Trends Pharmacol. Sci., 18, pp. 338-344, 1997.
115. Chen, J. F. et al., Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson’s disease, J. Neurosci., 21, p. RC143, 2001.
116. Veld, B. A. et al., Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease, N. Engl. J. Med., 345, pp. 1515-1521, 2001.
117. McGeer, P. L. and McGeer, E. G., The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases, Brain Res. Brain Res. Rev., 21, pp. 195-218, 1995.
118. Chen, H. et al., Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease, Arch. Neurol., 60, pp. 1059-1064, 2003.
119. Ross, G. et al., NSAID use and risk of Parkinson’s disease, Neurology, 60, p. A416, 2003.
120. Willems-Giesbergen, P. et al., Smoking, Alcohol, and Coffee Consumption and the Risk of PD: Results from the Rotterdam Study, Neurol., 54, p. A347, 2000.
121. Sasco, A. J. and Paffenbarger, Jr., R. S., Measles infection and Parkinson’s disease, Am. J. Epidemiol., 122, pp. 1017-1031, 1985.
122. Sasco, A. J. et al., The role of physical exercise in the occurrence of Parkinson’s disease, Arch. Neurol., 49, pp. 360-365, 1992.
123. Svenson, L. W., Regional disparities in the annual prevalence rates of Parkinson’s disease in Canada, Neuroepidemiology, 10, pp. 205-210, 1991.